Summary

Intracerebral hemorrhage (ICH) mortality estimates range from 37% (STICH trial) to 56% (SCHIPA trial). The Minimally Invasive Surgery plus t-PA for Intracerebral Hemorrhage Evacuation [MISTIE] trial was a phase 2 study sponsored by the National Institute of Neurological Disease and Stroke. The objective of the study was to determine whether reduction of clot size in ICH leads to lower mortality and better outcomes for patients.